Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization.
PEG-MGF
Overview
PEG-MGF is a pegylated derivative of Mechano Growth Factor designed to extend systemic half-life through the addition of polyethylene glycol moieties. Pegylation reduces renal clearance and proteolytic degradation, theoretically allowing for less frequent dosing and broader tissue distribution compared to unmodified MGF.
Mechanism of Action
The modified peptide retains the proposed satellite cell activation properties of native MGF.
Research Summary & Key Findings
No published clinical or preclinical studies have characterized the pharmacology, safety, or efficacy of PEG-MGF in any species. Available information is derived from unverified commercial sources and anecdotal reports. This compound has not been subjected to regulatory review and remains wholly investigational.
Clinical Status
PEG-MGF is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed — "PEG-MGF"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "PEG-MGF"
Registered interventional and observational studies, including status and phase.
- PubChem — "PEG-MGF"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Performance
Melanotan II
Research PhaseA synthetic cyclic analog of alpha-melanocyte stimulating hormone (alpha-MSH) that non-selectively activates melanocorti...
View detailsIGF-1 LR3 (Long-Arg3)
Research PhaseIGF-1 LR3 is a synthetic analogue of insulin-like growth factor 1 with an N-terminal extension of 13 amino acids and a s...
View detailsIGF-1 DES (1-3)
Research PhaseIGF-1 DES (1-3) is a truncated analogue of insulin-like growth factor 1 lacking the first three N-terminal amino acids (...
View detailsMGF (Mechano Growth Factor)
Research PhaseMechano Growth Factor is a splice variant of the IGF-1 gene expressed in response to mechanical stress on muscle tissue....
View detailsInvestigational Compound
PEG-MGF is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States. This profile is provided for educational understanding of the published research only.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.